Post-Menopause Skin Rejuvenation Study

The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.

NCT Number	NCT07205744
Lead Sponsor	Erevna Innovations Inc.
Conditions	Aesthetic, Menopause, Post-menopause, Injectables, Biostimulator, Hyaluronic Acid
Enrollment	50 participants
Start Date	2025-08-14
Primary Completion	2026-08-28 (estimated)
Study Completion	2026-09-28 (estimated)
Updated on ClinicalTrials.gov	2026-01-22